The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/?-catenin signaling pathway.

ABSTRACT: The ability to harness innate immunity is a promising solution for improving cancer immunotherapy. Interferon (IFN) induces expression of IFN-stimulated genes (ISGs) by activating the JAK-STAT signaling pathway to promote innate immunity and inhibit malignant tumor growth, but the functions and mechanisms of most ISGs in cancer regulation are unknown. As an innate immune effector, ISG12a promotes the innate immune response to viral infection. In this study, ISG12a was found to be expressed at low levels in gastrointestinal cancer, represented by hepatocellular cancer (HCC) and gastric cancer (GC), and it identified as a tumor suppressor that affects clinical prognosis. ISG12a silencing accelerated the malignant transformation and epithelial-mesenchymal transition of cancer cells. Mechanistically, ISG12a promoted ?-catenin proteasomal degradation by inhibiting the degradation of ubiquitinated Axin, thereby suppressing the canonical Wnt/?-catenin signaling pathway. Notably, ?-catenin was identified as a transcription factor for PD-L1. Inhibition of Wnt/?-catenin signaling by ISG12a suppressed expression of the immune checkpoint PD-L1, rendering cancer cells sensitive to NK cell-mediated killing. This study reveals a mechanism underlying the anticancer effects of IFN. Some ISGs, as represented by ISG12a, may be useful in cancer therapy and prevention. The identified interrelations among innate immunity, Wnt/?-catenin signaling, and cancer immunity may provide new insight into strategies that will improve the efficiency of immunotherapy.

SUBMITTER: Deng R 

PROVIDER: S-EPMC7784998 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature